Our Commitment
We are committed to developing and commercializing therapeutics that improve the health of people affected by chronic inflammatory and fibrotic diseases.
Learn More
Our Company
We are a clinical-stage company focused on treating inflammatory and fibrotic diseases by targeting the endocannabinoid system.
Our Science
Our focus on the endocannabinoid system is backed by an ever-expanding body of research and robust underlying science based on the endocannabinoid system as a master regulator of inflammation and fibrosis in the body.
Learn MoreLeading Endocannabinoid System-Targeting Pipeline
2
Lead Compounds
3
Ongoing Late-Stage Clinical Studies
600+
Compounds in Library
>350k
People Affected by Target Diseases
Join Our Team
We are high achievers, creative, innovative and above all else, passionate about what we do.
View Open Positions
View All News
Recent News
Investor Information
CRBP
Nasdaq
Volume
Market Cap
Change
